Cholesterol Guidelines for People with High Risk of Heart Attack
On July 13, 2004, a panel of experts from the National Cholesterol Education Program (NCEP) issued an update on cholesterol guidelines for men and women.
This is the second update to the guidelines since their inception in 1993, and is based on five major clinical trials of statin therapy (a cholesterol-lowering pharmaceutical treatment). All five of these trials showed that low low-density lipoprotein (LDL, or “bad”) cholesterol levels reduced risk of major coronary events (heart attack). The LDL levels reached in the trial were lower than the levels that were previously recommended.
As a result, recommendations were updated, particularly for high risk people. “Very-high risk” is defined as persons who have had a recent heart attack or who have known vascular disease plus other serious risk factors (diabetes, smoking, metabolic syndrome). The update did two things:
- It lowered the limit at which LDL levels are considered “too high” and potentially in need of drug treatment.
- For people at high risk for a heart attack the level dropped from 130 milligrams per deciliter (mg/dL)[3.4 mmol/L] to 100 mg/dL (2.6 mmol/L)
- Some very high risk people with LDL less than 100 mg/dL (2.6 mmol/L) could be treated with drugs
- It offers, as an option, lowering the ideal goal of LDL treatment from 100 mg/dL (2.6 mmol/L) to 70 mg/dL (1.8 mmol/L) in very high-risk people.
Cholesterol and Heart Disease
High levels of LDL cholesterol and/or low levels of high-density lipoprotein (HDL, or “good”) cholesterol, are major risk factors for heart attack and stroke. Heart attack and stroke are the first and third most common causes of death, respectively, in the United States today (cancer being the second). Each year, more than a million people in the US have a heart attack, and about half of them die from it.
All people over age 20 are advised to have their cholesterol levels checked every five years. In general:
- A total cholesterol level over 200 mg/dL (5.2 mmol/L) is considered moderately high in the general population
- LDL level over 130 mg/dL (3.4 mmol/L) is considered moderately high in the general population
- A person with a cholesterol level over 240 mg/dL (6.2 mmol/L) has more than twice the risk of heart disease compared to someone whose cholesterol is below 200 mg/dL (5.2 mmol/L)
A Run-Down of the Guidelines
The guidelines propose different recommendations depending on a person’s degree of risk of heart attack within the next ten years. This risk is determined by the presence of several risk factors, including history of heart attack or stroke, unstable or stable angina (chest pain), history of coronary artery procedures, evidence of clogged arteries (myocardial ischemia), diabetes, metabolic syndrome, high LDL cholesterol, low HDL cholesterol, high blood pressure, smoking, family history of heart disease, and age.
There are four major risk levels:
- High risk (over 20% chance of heart attack within ten years)
- Moderately high risk (10% to 20% chance)
- Moderate risk (under 10% chance)
- Lower risk (0-1 risk factors)
The new guidelines do not change cholesterol management recommendations for those at lower or moderate risk of heart attack, only for those at moderately high and high risk. Major changes are outlined in the table below:
|Risk Category||2004 recommendations based on LDL levels||Major change from 2001 recommendations?|
|High-risk and very high-risk||Yes|
* milligrams per deciliter (millimoles per liter)
The guidelines also now state that drug treatment for high-risk patients must be aggressive enough to achieve at least a 30% to 40% reduction in LDL levels. This indicates higher doses more often. Finally, the update maintains the importance of initiating therapeutic lifestyle changes (TLC) in high-risk persons—regardless of cholesterol level—since TLC can reduce cardiovascular risk in several ways besides lowering cholesterol.
By drug treatment, the guidelines refer mainly to the prescription of HMG-CoA reductase inhibitors, commonly known as “statins.” Statin medications work by blocking an enzyme (HMG-CoA reductase) that helps the body make cholesterol. Statins are distributed under the brand names:
Statin drugs have proven to be highly effective in reducing cholesterol levels. According to the FDA, statins can lower LDL cholesterol by as much as 60%. In a review of several studies, statins lowered cholesterol anywhere from 18% to 55%, while they increased healthy HDL levels by 5% to 15%. Beyond cholesterol levels themselves, statins have been shown to reduce risk of a coronary event by as much as 30% and mortality from such an event by 20%.
Furthermore, statins are generally highly accepted by patients and have few serious side effects. Common side effects include nausea, abdominal pain, gas, heartburn, and headache. More serious and rare side effects include muscle pain (myositis), joint pain, sleep disturbances, blurry eyesight, and decreased sexual ability. Very rarely, myositis can develop into rhabdomyolysis, a condition that can cause kidney failure and even death. Statins should not be used in people with active liver disease, or during pregnancy or lactation. Some drugs should be avoided while taking statins. Discuss your current regimen with your doctor before beginning statin therapy.
The TLC that the update recommends are basically a set of heart-healthy lifestyle changes. TLC includes:
- Eating a diet low in saturated fat and cholesterol
- Getting regular physical activity
- Achieving overall weight management
Moreover, diet and exercise have no adverse side effects and can help relieve multiple risk factors for heart disease. However, beneficial changes to diet and exercise habits are extremely difficult to achieve. People may be less likely to successfully lower their cholesterol in this way. Popping a pill is typically seen as the easier option.
Implications for the Future
In the end, diet and exercise remain the first-line treatment option for high cholesterol in those at low to moderate risk for heart disease. And, most certainly, they are measures of prevention that everyone should heed. The new guidelines recommend aggressive drug treatment only for those at high risk for an adverse coronary event.
The 2006 "Asteroid study" found that in very high risk individuals an average reduction of LDL by over 50% (to under 70 mg/dL [1.8 mmol/L]) led to actual reduction of coronary artery plaque. Although the plaque was only reduced overall by about 10%. These findings are important but further studies are needed to insure that the benefits mean decreased heart attack risk.
Some critics of the new guidelines argue that it’s unwise to call for such a major increase in drug prescription while allowing diet and exercise goals to fall by the wayside. They feel that dependence on drugs over willpower is ultimately a trend for the worse. Some even claim that members of the NCEP expert panel have financial ties to statin companies that will profit from the new guidelines.
On the other hand, according to the update’s authors, high-risk patients are still urged to incorporate TLC into their treatment regimen. However, the crucial fact is many of them simply cannot lower their cholesterol levels sufficiently, or fast enough, by diet and exercise alone. In essence, having failed to keep cholesterol levels lower, drug treatment is the best remaining option for those at high risk—especially when faced with heart attack and stroke.
Furthermore, new research suggests that intense statin therapy may be lifesaving for patients who have already experienced an acute coronary event, such as a heart attack, and are at severe risk for a repeat event.
American Heart Association
National Heart, Lung and Blood Institute
Heart and Stroke Foundation of Canada
Heart Healthy Kit: Public Health Agency of Canada
American Heart Association. Available at: http://www.americanheart.org.
Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227–239
Healy, B. Meet the cholesterol busters. US News & World Report . March 22, 2004. Available at: http://www.keepmedia.com/ShowItemDetails.do?item_id=395621&oliID=255&bemID=l/sjnYFhOG3jl2DVcd+7gQaa2208. Accessed September 13, 2004.
Henkel, J. Keeping cholesterol under control. FDA Consumer Magazine. Available at: http://www.fda.gov/fdac/features/1999/199_chol.html . Accessed on September 13, 2004.
Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):655-66.
National Heart, Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov.
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. [ASTEROID Investigators]. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-65.
Noonan, D. You want statins with that? Newsweek. July 28, 2003.
Squires, S. Need to Know: The Baycoll recall: how safe is your statin? The Washington Post. August 14, 2001, p.HE03.
Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. National Heart, Lung, and Blood Institute. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf . Accessed on September 13, 2004.
Last reviewed July 2008 by Dianne Scheinberg MS, RD, LDN
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2011 EBSCO Publishing All rights reserved.